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Introduction
Blood pressure (BP) is a quantitative trait that varies both
within subjects, according to diurnal patterns and longer-
term changes (across weeks or months because of changes
in environmental and physiologic influences), and be-
tween subjects, according to environmental factors and
genetic determinants. Measurement error adds a third
source of variability to BP quantification. These sources
of variability present a challenge for the detection of
genetic associations with BP given that the genetic com-
ponent is a relatively small portion of overall variability.
As it stands, the known genetic determinants of complex
quantitative traits, such as BP, are common polymor-
phisms with small allelic effects that require very large
sample sizes for detection. However, if measurement errors
could be reduced, the statistical power could be improved.
Hypertension is an important major cardiovascular risk
factor affecting approximately one-third of the adult
population globally and estimated to contribute to 13.5
million deaths yearly.1 Therefore, further improvements
in methods for signal detection in BP genetic association
studies are important.
Most epidemiologic and genetic association studies of BP
use single-visit, or ‘‘visit 1’’ (V1), measurements of BP.2–5
The standard protocol is to take multiple measurements at
a single point in time, discard the highest (first) value, and
average the rest to account for the ‘‘white-coat effect.’’6
Although these V1 BP traits have proved valuable, they
might be unrepresentative of an individual’s BP norm as
might be assessed from multiple BP measurements for an
individual across years. The use of such longitudinal
phenotype data, also known as repeated measures, might
alleviate some of the effects of measurement error and
similar sources underlying continuous traits, such as BP.
Simple averaging of repeated measurements presents a
straightforward opportunity to reduce phenotypic vari-
ability and thereby increase power to detect associations
while utilizing existing sample sizes. The utility of such
long-term average (LTA) procedures to study BP genetic
association has not been assessed. In this investigation,
we quantitatively explored the nature and degree of impro-
vement of genetic associations by LTA analyses of BP traits.
We performed genome-wide association studies (GWASs)
of LTA BP traits within multiple longitudinal community-
based cohorts in which BP traits have been measured at
multiple visits over several years of follow-up.7 For com-
parison, we also conducted parallel GWASs of V1 BP in
these same cohorts. We identified four loci associated
with BP traits in the LTA analyses; we also conducted
replication analyses by using independent samples with
V1 BP measurements and showed definitive replication
of two loci and nominal association at a third locus. We
compared the results of the LTA discovery analyses to the
corresponding V1 findings for the number of loci detected
and the characteristics of SNP associations within the
detected loci.50 The American Journal of Human Genetics 95, 49–65, July 3, 2014Material and Methods
Study Subjects
For the discovery analyses, the phenotype and genotype data of
46,629 individuals from eight participating longitudinal popula-
tion studies collaborating with the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consortium,7 the
Age, Gene/Environment Susceptibility (AGES) Reykjavik Study,
the Atherosclerosis Risk in Communities (ARIC) Study, the Cardio-
vascular Health Study (CHS), the Framingham Heart Study (FHS),
the Rotterdam Study (RS), the Women’s Genome Health Study
(WGHS), the Multi-Ethnic Study of Atherosclerosis (MESA), and
Coronary Artery Risk Development in Young Adults (CARDIA)
were analyzed for LTA BP and V1 BP trait genome-wide associa-
tions after adjustment for covariates. Only individuals of Euro-
pean ancestry, as confirmed by principal-component analysis of
genetic ancestry, were included in this analysis. For the replication
analyses, V1 BP data from 34,433 individuals across 17 cohorts
participating in the Global BP Genetics (GBPG) Consortium and
5,056 individuals in the Peking University – University of Michi-
gan Study of Atherosclerosis (PUUMA) were analyzed by identical
methods.5 All participants gave written informed consent for
participation in their respective studies and the conduct of genetic
research, and the studies in which the subjects were enrolled
were approved by their respective institutional review boards.
Detailed information on each participating study is provided in
the Supplemental Data, available online.BP Phenotypes
BP in each study was measured according to protocols described in
the cohort descriptions in the Supplemental Data. The traits
analyzed were systolic BP (SBP), diastolic BP (DBP), mean arterial
pressure (MAP), and pulse pressure (PP) as continuous traits. PP
was defined as SBP minus DBP, and MAP was defined as two-thirds
DBP plus one-third SBP. BP at each visit was corrected for antihy-
pertensive medication use by the addition of 10 mmHg to the
observed SBP value and 5mmHg to the observed DBP value. These
adjustments were also implemented prior to the calculation of
estimated off-treatment MAP and PP. To obtain the LTA BP traits,
we averaged repeated BP measurements for study participants;
individuals with two, three, or four repeated BP measures at least
1 year apart and within a 15-year timespan were included in our
analyses. For the ARIC cohort, we removed outliers greater than
4 SD units from the mean at each visit, but we did not remove
outliers from the other cohorts. Follow-up measurements beyond
15 years were not included in this analysis; individuals with only
one BP measurement were also excluded. At each study visit, we
performed linear regression, including adjustment for age, age-
squared, gender, body mass index, and study-specific corrections
for population substructure (based on principal-component anal-
ysis) to generate visit-specific BP residuals. These residual values
were subsequently averaged over all available visits, and the final
averaged residual was the LTA trait analyzed (termed LTA SBP,
LTA DBP, LTA MAP, and LTA PP). In the analyses of V1 BP traits,
BP values at the earliest visit among those included in this study
were analyzed. To facilitate comparisons of the LTA and V1 ana-
lyses, we conducted the V1 analyses in the same individuals
included in the LTA analyses. We adjusted V1 BP traits for anti-
hypertensive medication use and performed linear regression by
using covariate adjustment in a manner identical to what has
been done in prior V1 BP association analyses.4
Genotyping and Quality Control
Each study in the discovery LTA and V1 analyses genotyped sam-
ples by using high-density SNP marker platforms (Affymetrix
SNP6.0 in ARIC, CARDIA, and MESA; Affymetrix 500K in the
FHS; Illumina 370K in the AGES Reykjavik Study, CHS, and
WGHS; and Illumina 550K in the RS). Genotypes were imputed
to a set of approximately 2.5 million HapMap SNPs with the use
of HapMap Phase II CEU individuals (Utah residents with ancestry
from northern and western Europe from the CEPH collection) as a
reference and either MACH (ARIC, AGES Reykjavik Study, FHS,
MESA, RS, and WGHS), BEAGLE (CARDIA), or BIMBAM (CHS)
software. Similar methods were used in the replication cohorts.
Further details of SNP genotyping and quality-control measures
used for each cohort have been previously published.2,4,5
Statistical Association and Meta-analysis
Individual SNP association statistics were calculated for each SNP
meeting quality-control criteria via linear regression for LTA and
V1 BP traits. In each cohort, except in the FHS, association analysis
was performed with PLINK8 with linear regression under an addi-
tive genetic model. In the FHS, family structure was modeled with
a linear mixed-effects model implemented in R.9 Regression coef-
ficients and corresponding SEs for each SNP and trait were meta-
analyzed by inverse-variance-weighted meta-analysis to provide
the primary findings. Genomic control10 was applied to individual
study results and to the final meta-analysis results to control
effects possibly due to population stratification or cryptic related-
ness. The statistical-significance threshold was set at the p value of
5.0 3 108. For loci where variants showed significant associa-
tions, we examined the linkage-disequilibrium (LD) patterns
with SNAP;11 we assumed that loci with r2 < 0.3 were effectively
independent associations.
Replication Analyses Using V1 BP Traits
For replication analyses, we carried forward the five trait-locus
associations that we identified in our discovery LTA analyses but
that were not found in single-visit BP data in European-ancestry
individuals from GBPG and Chinese-ancestry individuals from
PUUMA. Details on the cohorts used for reproducibility analyses
are provided in the Supplemental Data. There are no sufficiently
sized replication cohorts with LTA traits to our knowledge, and
we elected to include as many samples as possible in a meta-anal-
ysis to increase power for the discovery analysis. Because the
follow-up association testing performed in the GBPG Consortium
and PUUMA participants was based on V1 data rather than trait
averages, as in our LTA discovery analyses, this experiment does
not constitute a true statistical ‘‘replication analysis’’ but rather a
biological one that might be partly underpowered.We used a Bon-
ferroni correction for the number of SNP-trait associations tested
for each of the four BP traits. To assess associations close to a
genome-wide significance threshold (p < 5 3 108), but not yet
meeting this criterion, we used V1 BP traits to test all LTA-analysis
SNPs with p < 5.0 3 107 in the GBPG Consortium V1 data.
Simulation of Statistical Power
We conducted computer simulations to evaluate the change in
statistical power to detect associations by using LTA versus V1 BP
traits as a function of sample size and effect size. The genome-
wide significance level was set to p < 5 3 108. We simulated
phenotypic data across four visits, as well as SNP data with
different allele frequencies and different effect sizes. PhenotypeThdata were simulated from a multivariate normal distribution
with correlation structures based upon those observed in the
ARIC Study. Next, we simulated genotype for a single SNP by
setting the minor allele frequency to 0.05, 0.1, 0.2, 0.3, or 0.4
and then randomly drawing genotypes as 0, 1, or 2, with probabil-
ities p2, 2pq, or q2, respectively, by assuming Hardy-Weinberg
equilibrium. We tested three scenarios in these simulation tests:
(1) in V1, we took simulated SBP measurements from V1 only
and ignored the following three visits and regressed SBP onto
each SNP; (2) in LTA, we averaged the four visits and performed
a linear regression of SBP onto each SNP; (3) in a third analysis,
using generalized estimating equations (GEEs), we included data
from all four visits in a model with an exchangeable correlation
structure between the visits. In initial experiments, assuming a
sample size of 1,000, we repeated our simulations 10,000 times
(with independent sampling of both phenotype and genotype
data from their distributions) and computed the proportion of
times when a SNP was significantly associated with the trait. To
estimate power in a more representative case, such as for the
ARIC cohort, we assumed a sample size of 10,000 and repeated
the simulations.Analysis of Signal Enrichment by LTA in Comparison
with V1 BP Trait Associations
Using the LTA and V1 association results on the same 46,553
individuals, we used the Kolmogorov-Smirnov (K-S) statistic
to compare each region’s –log10 p values meeting criteria for
genome-wide significance (p < 5 3 108) to evaluate whether
LTA results showed departure of the association statistics from
the distribution of corresponding V1 association statistics. This
analysis was performed to compare LTA SBP with V1 SBP and to
compare LTA DBP with V1 DBP. Regions with at least one SNP
marker with p < 5 3 108 in either LTA or V1 analyses were
selected for enrichment analysis. Regions were defined by the
lead SNP and by the LD-pruned list of SNPs in the region (r2> 0.3).Analysis of Expression Quantitative Trait Loci
For the purpose of annotating our findings, we searched for
primary SNPs identified in our LTA analyses and LD proxies
against a collected database of expression SNP (eSNP) results
from several tissues. Using SNAP,11 we identified alias rsIDs
for rs445925. SNAP also helped us identify four further proxy
SNPs (rs72654473, rs80125357, rs7412, and rs283810) in LD
(r2 > 0.5) in four HapMap builds. SNP rsIDs were searched for
primary SNPs and LD proxies against a collected database of
eSNP results.12–60 The collected eSNP results met criteria for
statistical thresholds for association with gene transcript levels,
as described in the original papers, for several tissues. mRNA
quantitative trait loci (QTLs) were also queried for gluteal and
abdominal adipose.12
Additional expression QTL (eQTL) data were integrated from
online sources, including ScanDB, the Broad Institute GTex
browser, and the Prichard Lab (see Web Resources). Data on cere-
bellum, parietal lobe, and liver eQTLs were downloaded from
ScanDB; cis-eQTLs were limited to those with p < 1.0 3 106, and
trans-eQTLs were limited to those with p < 5.0 3 108. The top
1,000 eQTL results were downloaded (on November 26, 2013)
from the GTex Browser at the Broad Institute for nine tissues:
thyroid, leg skin (sun exposed), tibial nerve, tibial artery, skeletal
muscle, lung, heart (left ventricle), whole blood, and subcutaneous
adipose.14 All GTex results had associations with p < 8.43 107.e American Journal of Human Genetics 95, 49–65, July 3, 2014 51
Table 1. Summary of Discovery Cohorts, Sample Sizes, and Visits for the LTA Analyses
Cohort
No. of
Visits
No. of
Individuals
Age at First
Visit in
Years (SD)
Age at Last
Visit in
Years (SD)
Mean
BMI in
kg/m2 (SD)
Mean
SBP in
mmHg (SD)
Mean
DBP in
mmHg (SD)
Antihypertensive
Therapy at
First Visit
Antihypertensive
Therapy at
Last Visit
AGES Reykjavik
Study
2 526 66.0 (7.0) 78.5 (5.9) 26.2 (3.9) 141.4 (18.8) 82.1 (8.7) 24% 65%
ARIC Study 4 7,310 54.3 (5.7) 63.1 (5.6) 27.0 (4.9) 118.5 (17.0) 71.7 (10.0) 26% 40%
CARDIA 4 1,671 32.6 (3.3) 45.8 (3.4) 25.6 (5.1) 106.3 (11.4) 67.8 (9.5) 0.9% 11%
CHS 4 3,159 72.4 (5.4) 75.3 (5.4) 26.3 (4.5) 138.7 (22.5) 72.2 (11.9) 35% 41%
FHS original
cohort
4 660 74.4 (4.5) 85.6 (4.0) 26.7 (4.6) 148.1 (23.5) 72.9 (11.3) 49% 60%
FHS offspring 4 3,235 50.7 (9.8) 61.0 (9.5) 26.8 (4.9) 127.4 (20.0) 79.7 (10.6) 15% 32%
MESA 4 2,414 62.7 (10.2) 66.9 (10.2) 27.7 (5.1) 123.5 (20.5) 70.1 (9.9) 33% 45%
RS 1 4 4,710 67.9 (8.2) 75.5 (6.2) 26.3 (3.6) 140.4 (22.8) 74.9 (11.7) 22% 37%
RS 2 4 1,535 63.7 (2.3) 67.9 (7.2) 27.2 (4.1) 143.4 (21.6) 79.7 (11.1) 21% 30%
WGHS 3 21,409 54.7 (7.0) 65.2 (6.8) 25.9 (4.9) 124.8 (15.4) 77.3 (9.7) 13% 43%
Abbreviations are as follows: AGES, Age, Gene/Environment Susceptibility; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CARDIA, Coronary
Artery Risk Development in Young Adults; CHS, Cardiovascular Health Study; DBP, diastolic blood pressure; FHS, Framingham Heart Study; MESA, Multi-Ethnic
Study of Atherosclerosis; RS, Rotterdam Study; SBP, systolic blood pressure; and WGHS, Women’s Genome Health Study.Results
Longitudinal Analysis of BP
The discovery analyses of LTA BP traits were conducted in a
sample size of 46,629 individuals, whose characteristics,
including age, sex, and trait summaries, are summarized
in Table 1. Our overall study design is shown in Figure S1.
By requiring each study participant included in the LTA
analyses to have two or more BP measurements, we ex-
cluded a total of 8,887 individuals with data at V1 only
across the cohorts (Table S1) and consequently analyzed
46,553 individuals for both the LTA and V1 analyses re-
ported. Information on the specific visits included in the
LTA analyses is provided in Table S2. Phenotypic correla-
tions were performed in the ARIC cohort on the average
LTA and V1 residuals we analyzed (Figure 1) and showed
r > 0.7 (the V1 measurement was included in the LTA
measurement, and thus correlation was expected).
Meta-analysis of GWASs for LTA BP Traits for
Discovery of Genetic Associations
When individual cohort results were combined via inverse-
variance-weighted meta-analysis, 488 SNP-trait associa-
tions at 19 independent loci (r2 < 0.3 between SNPs)
reached genome-wide significance (p < 5 3 108) (Table
2). Quantile-quantile p value plots are shown in Figure S2,
and genomic-control inflation factors (lGC) ranged from
1.055 to 1.095 for the LTA traits (Table S3) and were com-
parable for V1 SBP (1.076) and V1 DBP (1.066). The log10
p value genome-wide association plots for SBP and DBP
are shown in Figure 2, and those forMAP and PP are shown
in Figure S3. In total, there were 39 trait-locus combina-
tions with at least one genome-wide significant associa-
tion. We identified 13 loci associated with LTA SBP, ten52 The American Journal of Human Genetics 95, 49–65, July 3, 2014loci associated with LTA DBP, 11 loci associated with LTA
MAP, and five loci associated with LTA PP (all are sum-
marized in Table 2). The complete set of SNPs identified
is provided in Table S4. For the purpose of annotating
the associations identified in our analyses, index SNPs
and proxies were checked for eQTL associations. Some
SNPs showed associations with expression levels, includ-
ing with genes with known BP roles (e.g., AGT [MIM
106150] and NPR3 [MIM 108962]). The loci identified in
this analysis, but not previously described, did not show
new eQTL associations, suggesting that mechanisms of
effect are not mediated through regulation of gene expres-
sion. The full results are summarized in Table S5.
Replication Studies
For follow-up, we focused on the five SNP-trait associations
that we identified in the LTA analyses but that had not
been identified in prior studies of V1 BP (Table 3). We con-
ducted replication analyses of independent samples not
studied in the discovery work by using pooled V1 data
from 23 GBPG Consortium cohorts—for a total sample
size of 34,433 individuals of European ancestry5—and
5,605 Han Chinese individuals from PUUMA. Clinical
summaries have been previously published for the GBPG
Consortium. 5 Clinical summaries for PUUMA are pro-
vided in Table S6. We tested the lead SNP from each
region identified in our LTA analyses for its associa-
tion with each corresponding V1 trait and corrected for
the number of regions tested (the p value threshold was
0.05 / 1 ¼ 0.05 for LTA SBP, LTA DBP, and LTA MAP and
0.05 / 2 ¼ 0.025 for LTA PP). The GBPG Consortium and
PUUMA results were combined in a fixed-effects meta-
analysis and demonstrated significant association between
chromosomal region 2p23 (KCNK3 [MIM 603220]) and
Figure 1. LTA versus V1 SBP and DBP Re-
siduals in the ARIC Cohort
The final averaged residuals for LTA SBP
and LTA DBP (n ¼ 8,778) are plotted on
the y axis against the corresponding V1
SBP and V1 DBP residuals on the x axis.both MAP (p ¼ 0.0091) and SBP (p ¼ 0.0079) and between
chromosomal region 6p21 (CRIP3) and PP (p ¼ 0.0041), all
of which met the Bonferroni-corrected threshold (Table 4).
A nominal association (p < 0.05) was noted between re-
gion 7p13 (IGFBP3 [MIM 146732]) and PP (Table 4). In
the individual replication groups, we observed positive
replication for two SNP-trait associations in the GBPG
Consortium V1 replication analyses (p ¼ 0.030 between
chromosomal region 2p23 [KCNK3] and SBP and p ¼
0.0067 between region 6p21 [CRIP3] and PP). In two of
the remaining loci, there was a nonsignificant trend (p <
0.10) of association (between 2p23 [KCNK3] and MAP
and between 7p13 [IGFBP3] and PP). In the PUUMA study,
replication was observed for the association between chro-
mosome region 2p23 (KCNK3) and MAP (p ¼ 0.0079).
Plots of the –log p value for these regions are shown in
Figure S6.
To assess overall rates of replication, including for
known signals, in the GBPG Consortium V1 data, we as-
sessed the associations for all SNPs where the LTA associa-
tion analyses provided p < 5.0 3 107 (213 SNPs for LTA
SBP, 186 SNPs for LTA DBP, 273 SNPs for LTA MAP, and
225 SNPs for LTA PP). In the analysis of these top SNPs,
we reproduced associations (p < 5 3 107) in the GBPG
Consortium V1 data for 13/16 DBP-associated loci, 14/18
SBP-associated loci, 15/18 MAP-associated loci, and seven
PP-associated loci (Table S7). Restricting testing to the loci
with genome-wide significant association results in the
LTA analyses and association p values < 5 3 108 resulted
in reproduction of associations at 11/13 SBP-associated
loci, 8/10 DBP-associated loci, 9/11 MAP-associated loci,
and 4/4 PP-associated loci (Table S7). Thus, the overall
replication rates in this analysis were 83% (49/59) and
84% (32/38) for p< 53 107 and p< 53 108, respectively.
Comparing LTA and V1 BP Association Patterns to
Evaluate the Impact of LTA
Using exactly the same samples and genotypes as in the
discovery LTA analyses, we conducted a secondary analysisThe American Journal of Hof V1 BP traits for the purpose of char-
acterizing the difference between LTA
BP and V1 BP associations. Overall,
we identified more loci meeting
genome-wide significance thresholds
in the LTA analyses than in the V1
analyses. In the LTA analyses, we
observed 488 SNP-trait associations
with p < 5 3 108 in 19 loci (117 for
LTA SBP, 96 for LTA DBP, 155 for LTAMAP, and 120 for LTA PP); in the corresponding V1 ana-
lyses, we observed 402 SNP-trait associations with p <
5 3 108 (122 for V1 SBP, 126 for V1 DBP, 153 for V1
MAP, and 1 for V1 PP) (Figure S4). At the p value threshold
of 53 107, we identified 897 SNP-trait associations in the
LTA analyses (213 for LTA SBP, 186 for LTADBP, 273 for LTA
MAP, and 225 for LTA PP) and 570 SNP-trait associations
in the V1 analyses (163 for V1 SBP, 182 for V1 DBP, 222
for V1 MAP, and 3 for V1 PP) (Table S8). Overall, these
data show that the LTA analyses yielded a greater number
of significant associations. The V1 results in the same sam-
ples as the LTA analyses are shown for the top LTA loci in
Table 5; they show a large degree of concordance in both
analyses but a greater yield from the LTA analyses.
To further evaluate the impact of LTA, we performed
additional comparisons between the LTA and V1 BP asso-
ciation statistics by focusing on SBP and DBP results only.
Comparisons of beta estimates, SEs, and chi-square values
demonstrated the impact of averaging on the SE of the
phenotypic estimate (Figure S5). Correlations between
the genome-wide LTA and V1 association statistics were
high; the correlations of standardized effect estimates
were r2 ¼ 0.82 for SBP and r2 ¼ 0.80 for DBP. When
restricted to the sentinel SNP-trait associations for SBP
(13 SNPs) and DBP (ten SNPs), the correlations of the beta
estimates were higher at r2 ¼ 0.99 for both SBP and DBP.
In comparisons of the LTA and V1 association results,
the p values for LTA SBP and LTA DBP summary results
were generally lower than the corresponding V1 results
(Table 5). However, in some regions, the association
p values were lower in the V1 analyses, demonstrating
that LTA might not enrich association signals in all
genomic regions. We assessed the distribution of the lead
LTA-identified SNPs (p < 5 3 108) across all loci by
comparing the number of SNPs found at the tails of the
ranked p value distribution for each trait in the LTA and
V1 analyses. In each of the four traits, there was substantial
enrichment of signals at the tails of the p value distribution
in the LTA analyses (Table S9).uman Genetics 95, 49–65, July 3, 2014 53
Table 2. Summary of LTA Discovery Analyses for Loci with SNP-Trait Association p Values < 5 3 108
SNP ID Allele Chr Position In Gene Closest Gene Genes in LD Block Beta SE p Value
LTA DBP
rs13306561 a 1 11,788,391 MTHFR MTHFR NPPA-AS1, CLCN6, MTHFR, NPPA 0.48 0.07 2.08 3 1010
rs2004776 t 1 228,915,325 AGT AGT AGT 0.35 0.06 3.20 3 108
rs7599598a a 2 96,715,567 FER1L5 FER1L5 FER1L5 0.31 0.05 2.91 3 108
rs198823 t 6 26,230,912 NA HIST1H2BC HIST1H1T, HIST1H4A, HIST1H2BB,
HIST1H3C, HIST1H3A, HIST1H2BC,
TRIM38, HFE, HIST1H2AB, HIST1H2AC,
HIST1H3B, HIST1H4B, HIST1H4C,
HIST1H1A, HIST1H1C
0.33 0.06 6.57 3 109
rs12258967 c 10 18,767,965 CACNB2 CACNB2 CACNB2 0.35 0.06 2.48 3 109
rs12244842 t 10 63,109,192 C10orf107 C10orf107 C10orf107 0.38 0.06 7.05 3 109
rs2681472 a 12 88,533,090 ATP2B1 ATP2B1 ATP2B1, LOC338758 0.52 0.07 4.01 3 1013
rs3184504 t 12 110,368,991 SH2B3 SH2B3 TRAFD1, PTPN11, RPL6, ALDH2,
ATXN2, TMEM116, ERP29, MAPKAPK5,
ADAM1, SH2B3, C12orf51, C12orf47,
NAA25, ACAD10, BRAP
0.39 0.05 6.08 3 1013
rs1133323 t 15 72,999,278 NA COX5A CSK, CPLX3, COX5A, SCAMP2, C15orf17,
MPI, ULK3, LMAN1L, MIR4513
0.33 0.05 2.66 3 109
rs6092743 a 20 57,133,765 NA C20orf174 NA 0.50 0.08 1.11 3 108
LTA SBP
rs880315 t 1 10,719,453 CASZ1 CASZ1 MTOR, C1orf127, TARDBP, EXOSC10,
C1orf187, FBXO2, FBXO6, MAD2L2,
MTHFR, FBXO44, SRM, PTCHD2, MASP2,
UBIAD1, CASZ1, ANGPTL7, AGTRAP
0.71 0.10 7.98 3 1012
rs13306561 a 1 11,788,391 MTHFR MTHFR NPPB, NPPA-AS1, CLCN6, MTHFR, NPPA 0.88 0.12 6.38 3 1012
rs1275988a t 2 26,767,868 NA KCNK3 KCNK3 0.60 0.09 2.61 3 1010
rs6712094 a 2 164,751,706 NA GRB14 NA 0.60 0.10 9.89 3 109
rs7733331 t 5 32,864,603 NA C5orf23 NPR3 0.55 0.09 5.38 3 109
rs12705390 a 7 106,198,013 NA PIK3CG NA 0.63 0.11 3.17 3 108
rs12258967 c 10 18,767,965 CACNB2 CACNB2 CACNB2 0.63 0.10 4.53 3 1010
rs7070797 a 10 63,221,779 NA C10orf107 C10orf107 0.74 0.13 4.30 3 108
rs2681472 a 12 88,533,090 ATP2B1 ATP2B1 ATP2B1, LOC338758 0.95 0.12 1.04 3 1014
rs4766578 a 12 110,388,754 ATXN2 ATXN2 TRAFD1, PTPN11, RPL6, ALDH2, ATXN2,
TMEM116, ERP29, MAPKAPK5, ADAM1,
SH2B3, C12orf51, C12orf47, NAA25,
ACAD10, BRAP
0.56 0.09 2.82 3 109
rs35444 a 12 114,036,820 NA TBX3 NA 0.55 0.09 1.47 3 108
rs11072518 t 15 73,021,663 NA COX5A CSK, CPLX3, COX5A, SCAMP2, C15orf17,
CYP1A2, MPI, ULK3, LMAN1L, MIR4513
0.57 0.09 6.54 3 109
rs6092743 a 20 57,133,765 NA C20orf174 NA 0.84 0.14 2.25 3 108
LTA MAP
rs880315 t 1 10,719,453 CASZ1 CASZ1 CASZ1 0.46 0.07 5.49 3 1011
rs13306561 a 1 11,788,391 MTHFR MTHFR NPPB, NPPA-AS1, CLCN6, MTHFR, NPPA 0.61 0.08 1.83 3 1012
rs2004776 t 1 228,915,325 AGT AGT AGT 0.42 0.07 1.18 3 108
rs1275988a t 2 26,767,868 NA KCNK3 KCNK3 0.39 0.06 1.51 3 109
rs12258967 c 10 18,767,965 CACNB2 CACNB2 CACNB2 0.45 0.07 4.98 3 1011
rs2166122 t 10 63,193,080 C10orf107 C10orf107 C10orf107 0.48 0.08 1.88 3 109
rs2681472 a 12 88,533,090 ATP2B1 ATP2B1 ATP2B1, LOC338758 0.69 0.08 1.77 3 1016
(Continued on next page)
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Table 2. Continued
SNP ID Allele Chr Position In Gene Closest Gene Genes in LD Block Beta SE p Value
rs3184504 t 12 110,368,991 SH2B3 SH2B3 CUX2, FAM109A, TRAFD1, PTPN11, RPL6,
ALDH2, ATXN2, TMEM116, ERP29,
MAPKAPK5, ADAM1, SH2B3, C12orf51,
C12orf47, NAA25, ACAD10, BRAP
0.45 0.06 1.68 3 1012
rs35444 a 12 114,036,820 NA TBX3 NA 0.36 0.06 3.20 3 108
rs11072518 t 15 73,021,663 NA COX5A CSK, CPLX3, COX5A, SCAMP2, C15orf17,
CYP1A2, MPI, ULK3, LMAN1L, MIR4513
0.43 0.06 8.95 3 1011
rs6092743 a 20 57,133,765 NA C20orf174 NA 0.64 0.10 3.60 3 1010
LTA PP
rs880315 t 1 10,719,453 CASZ1 CASZ1 CASZ1 0.42 0.07 5.45 3 109
rs7650227 t 3 41,769,941 ULK4 ULK4 ULK4 0.50 0.08 2.84 3 109
rs10948071a t 6 43,388,691 NA CRIP3 CRIP3, SLC22A7, ZNF318 0.38 0.07 9.06 3 109
rs2949837a a 7 45,960,903 NA IGFBP3 NA 0.40 0.07 2.94 3 108
rs12705390 a 7 106,198,013 NA PIK3CG NA 0.59 0.08 5.40 3 1014
Abbreviations are as follows: Chr, chromosome; DBP, diastolic blood pressure; LTA, long-term average; MAP, mean arterial pressure; NA, not available; PP, pulse
pressure; and SBP, systolic blood pressure.
aBP-associated loci found in our LTA analyses.To study the general magnitude of the effect of LTA on
the statistical power to detect SNP associations, we carried
out a set of simulation experiments. Correlations of SBP
and DBP across the four visits included in the ARIC anal-
ysis ranged from r ¼ 0.60 to r ¼ 0.73 (Table S10A). Using
unstructured correlation structures resulted in similar esti-
mates (data not shown). The simulations showed that LTA
increases power by about 20% in most cases (Tables S10B
and S10C). It can be a much larger increase if the initial po-
wer is very low. GEEs do not improve power over LTA by
any significant amount. By comparison, our LTA results
are largely consistent with the simulation results.
The simulation results are corroborated by the com-
parison of our LTA and V1 results: compared with V1 an-
alyses, LTA analyses identified 17 additional trait-locus
associations (two with DBP, seven with SBP, three with
MAP, and five with PP, for a total of nine additional inde-
pendent loci).
Enrichment Analysis
To further examine the extent of signal enrichment by
LTA and to characterize regions with a lack of enrichment
by LTA, we conducted a number of analyses. First, we
plotted the V1 and LTA association statistics for all regions
identified by either the LTA or the V1 analyses. Chromo-
somal region 12q21 (ATP2B1), which shows the strongest
GWAS association signal for BP to date, and region 2p23
(KCNK3), which demonstrated enrichment of the associa-
tion signal in our study, are shown in Figure 3; all other loci
are shown in Figure S7. We also aligned LTA and V1 results
for each region and calculated the K-S statistic for each re-
gion (Figures S8 and S9) and found that evidence of enrich-
ment by the LTA procedure was specific to 21 trait-locus
associations and that a significant lack of enrichment, orThstronger V1 association signal, was a clear pattern noted
at eight other trait-locus associations. One region showed
mixed effects: some SNP associations were enriched by
LTA, and some were significantly stronger in the V1 ana-
lyses (chromosomal region 3p22, ULK4). In 15 regions,
the results were not significantly enriched in either the
LTA or the V1 analyses (Table S11). Specifically, we identi-
fied enrichment by LTA in six regions for SBP (chromosome
1 nearMTHFR [MIM 607093], chromosome 2 near KCNK3,
chromosome 2 near GRB14 [MIM 601524], chromosome 5
near C5orf23, chromosome 7 near PIK3CG [MIM 601232],
and chromosome 10 near C10orf107); in four regions for
DBP (chromosome 1 in MTHFR, chromosome 5 near EBF1
[MIM 164343], chromosome 6 near HFE [MIM 613609],
and chromosome 12 in SH2B3 [MIM 605093]); in four
regions for MAP (chromosome 1 in CASZ1 [MIM 609895],
chromosome 1 in MTHFR, chromosome 2 near KCNK3,
and chromosome 12 in ATP2B1 [MIM 108731]); and in
three regions for PP (chromosome 6 near CRIP3, chro-
mosome 7 near IGFBP3, and chromosome 7 near PIK3CG).Discussion
This study was designed to assess the effect of utilizing
LTA of BP traits, from longitudinal measures, to detect
genetic associations. The motivation for our analyses
was to use a procedure that would reduce measurement
errors and other variation sources that lower the statistical
power of the analysis. In our LTA analyses, we discovered
39 trait-variant associations and uniquely identified four
loci (2p23 [near KCNK3] for SBP and MAP, 2q11.2
[in FER1L5] for DBP, 6p21 [near CRIP3] for PP, and
7p13 [near IGFBP3] for PP). Replication testing in 34,433e American Journal of Human Genetics 95, 49–65, July 3, 2014 55
Figure 2. GWASs: –Log p Plots for LTA and V1 SBP and DBP Analyses
GWAS –log p plots compare (A) LTA SBP and V1 SBP and (B) LTA DBP and V1 DBP. Regions containing one or more SNPs with p < 5 3
108 are in red, and suggestive associations (p < 5 3 107) are shown in blue.independent European-ancestry samples and 5,600 Chi-
nese-ancestry samples with V1 BP data definitively
confirmed these associations at two (KCNK3 andCRIP3)
of the four discovered loci, and these were carried forward
to replication analyses. At IGFBP3, we found a nominal as-
sociation not meeting statistical significance after adjust-
ment for multiple-hypothesis testing. When we compared
LTA and V1 associations in the same group of individuals,
we observed that in some loci, the p values of LTA traits
were two orders of magnitude lower than the correspond-
ing V1 BP traits. Overall, we demonstrated enrichment of
association signals with LTA by detecting a larger number
of SNPs and loci. Through computer simulations, we esti-
mated this increase in statistical power by LTA to be
~20%, consistent with the results of our analyses of BP
data.
Several sources of variability of BP affect the ability to
detect genetic associations. First, there is physiologic, in-
traindividual variability following both diurnal patterns
and longer-term and less predictable patterns as a result56 The American Journal of Human Genetics 95, 49–65, July 3, 2014of individual-specific factors, such as changes in dietary
intake of sodium. Second, there is variation in BP measure-
ment as a result of imprecise measurement techniques and
biases such as digit preference.61 Noise in themeasurement
of a quantitative trait adversely affects power to detect
association signals, essentially by increasing the variance
of the trait, and the study of BP in particular has been a
notable example in which phenotypic imprecision has
hampered our ability to detect alleles.62 Examples of this
impact are also available in clinical pathology, where the
variance for analysis measurements can be high for specific
analyses, and when up to 20% of the variance derives from
intraindividual variation and measurement error, this can
result in a 15%–20% loss in power to detect statistical
associations.63 Averaging has been studied in a number
of epidemiologic applications, to BP and other continuous
traits characterized by variability, where it can improve
parameter estimation.64–67
We examined the statistical properties of the LTA pro-
cedure, and although it is a relatively simple procedure,
Table 3. Loci with SNP-Trait Association p Values < 5 3 108 from LTA Discovery Analyses
Trait SNP ID Allele Locus Position Closest Gene Beta SE p Value
LTA DBP rs7599598 a 2q11 96715567 FER1L5 0.31 0.05 2.91 3 108
LTA SBP rs1275988 t 2p23 26767868 KCNK3 0.60 0.09 2.61 3 1010
LTA MAP rs1275988 t 2p23 26767868 KCNK3 0.39 0.06 1.51 3 109
LTA PP rs10948071 t 6p21 43388691 CRIP3 0.38 0.07 9.06 3 109
LTA PP rs2949837 a 7p13 45960903 IGFBP3 0.40 0.07 2.94 3 108
Abbreviations are as follows: DBP, diastolic blood pressure; MAP, mean arterial pressure; LTA, long-term average; PP, pulse pressure; and SBP, systolic blood
pressure.there are several important implications of our results.
First, LTA is expected to describe a more accurate estimate
of an individual’s long-term BP value. We averaged two,
three, or four visits—not the maximum number of avail-
able measurements, which could have been up to 15 visits
in some cohorts—in order to keep phenotypic SEs gener-
ally comparable across the cohorts we studied. Other
age-related trends, such as changes in body mass index
(BMI), were accounted for in the visit-specific adjustment
of BP traits by BMI at the corresponding visit. In published
V1 BP association studies, finding associations for DBP
has been more challenging, and there have generally
been fewer findings for DBP than for SBP. Our results
show a similar trend.
The overall improvement in power with LTA has impor-
tant implications for study design in genetic association
studies. For traits with few extraneous sources of ‘‘noise,’’
such as height, weight, or blood analyses measured with
standardized clinical assays (such as lipid and hematology
traits), GWASs have generally been fruitful in that they
yield many positive associations explaining up to ~10%
of the phenotypic variance of these continuous traits. In
the case of traits with many and varied sources of noise,
such as BP, measures to improve phenotypic accuracy
help identify additional loci. Typically, increasing sample
size is the key strategy to increase statistical power, and
this has been done widely in GWASs to detect associations
with modest effect sizes. However, in the GWAS and meta-Table 4. Reproducibility-Analysis Association Results in the GBPG Con
Trait SNP ID
Closest
Gene
GBPG Consortium V1 BP
Association Results
PUUMA
Associ
Beta SE p Value Beta
V1 DBP rs7599598 FER1L5 0.04 0.08 6.14 3 101 0.001
V1 SBP rs1275988a KCNK3 0.26 0.12 2.98 3 102 0.79
V1 MAP rs1275988a KCNK3 0.16 0.08 5.68 3 102 0.72
V1 PP rs10948071a CRIP3 0.24 0.09 6.69 3 103 0.25
V1 PP rs2949837 IGFBP3 0.15 0.09 9.96 3 102 0.34
Abbreviations are as follows: BP, blood pressure; DBP, diastolic blood pressure; G
pressure; PUUMA, Peking University – University of Michigan Study of Atheroscle
aLoci meeting a Bonferroni-corrected replication threshold.
Thanalysis approach, inclusion of additional cohorts to a
meta-analysis might increase potential phenotypic and ge-
netic variability, which cannot be adequately corrected for
in the analysis. Our results demonstrate that trait aver-
aging is a practical way to increase statistical power for
quantitative phenotypes with substantial variability, such
as BP, in population cohorts with longitudinal BP data.
One surprising finding was that some of the associations
identified in the V1 analyses were not detected in the
LTA analyses, and in specific regions, the V1 analyses
yielded stronger significance. A statistical hypothesis for
this finding is regression to the mean, or winner’s curse,
in the LTA analyses. Biologic hypotheses include possible
physiologic intraindividual sources of variation, such as
the known circadian pattern of BP, or variation of clinical
relevance for which mechanisms are not known.68 As
such, we recommend utilizing LTA to improve the pre-
cision of highly variable continuous traits for which
measurement error or uncertainty is known. Further, we
recommend considering concurrent analysis of LTA and
single measurement of traits and an evaluation of any of
the differences between the two sets of results for possible
insights into the mechanism of the genetic association.
LTA can also capture additional useful information. LTA
BP is a clinically relevant phenotype and is associated
with cardiovascular disease (CVD) events and target organ
damage, an intermediate phenotype for subsequent CVD
events.64,69 Although single ‘‘casual’’ BP measurements insortium and PUUMA V1 BP Analyses
V1 BP
ation Results
Meta-analysis of GBPG Consortium
and PUUMA V1 BP Association Results
SE p Value Beta SE p Value
0.21 9.95 3 101 0.03 0.07 6.40 3 101
0.39 4.54 3 102 0.30 0.11 7.93 3 103
0.27 7.85 3 103 0.21 0.08 9.08 3 103
0.27 3.56 3 101 0.24 0.08 4.17 3 103
0.26 1.94 3 101 0.17 0.09 4.68 3 102
BPG, Global Blood Pressure Genetics; MAP, mean arterial pressure; PP, pulse
rosis; SBP, systolic blood pressure; and V1, visit 1.
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Table 5. The LTA Lead SNPs Were Investigated in the V1 Analysis of the Same Cohorts and Study Participants
SNP ID Allele Chr Position
Closest
Gene
LTA BP Results in Discovery Samples V1 BP Results in LTA Discovery Samples LTA-V1 Differences
Trait Beta SE p Value Trait Beta SE p Value D Beta D p Value
rs880315 t 1 10,719,453 CASZ1 LTA SBP 0.71 0.10 7.98 3 1012 V1 SBP 0.68 0.11 7.20 3 109 3.05 3 102 7.19 3 109
rs13306561 a 1 11,788,391 MTHFR LTA SBP 0.88 0.12 6.38 3 1012 V1 SBP 0.76 0.14 1.11 3 107 1.21 3 101 1.11 3 107
rs1275988 t 2 26,767,868 KCNK3 LTA SBP 0.60 0.09 2.61 3 1010 V1 SBP 0.47 0.10 1.38 3 105 1.33 3 101 1.38 3 105
rs6712094 a 2 164,751,706 GRB14 LTA SBP 0.60 0.10 9.89 3 109 V1 SBP 0.58 0.11 5.22 3 107 1.49 3 102 5.12 3 107
rs7733331 t 5 32,864,603 C5orf23 LTA SBP 0.55 0.09 5.38 3 109 V1 SBP 0.41 0.10 1.41 3 104 1.46 3 101 1.41 3 104
rs12705390 a 7 106,198,013 PIK3CG LTA SBP 0.63 0.11 3.17 3 108 V1 SBP 0.54 0.12 2.63 3 105 8.91 3 102 2.62 3 105
rs12258967 c 10 18,767,965 CACNB2 LTA SBP 0.63 0.10 4.53 3 1010 V1 SBP 0.64 0.11 1.53 3 108 1.04 3 102 1.48 3 108
rs7070797 a 10 63,221,779 C10orf107 LTA SBP 0.74 0.13 4.30 3 108 V1 SBP 0.73 0.14 1.17 3 106 1.58 3 102 1.12 3 106
rs2681472 a 12 88,533,090 ATP2B1 LTA SBP 0.95 0.12 1.04 3 1014 V1 SBP 0.93 0.13 1.69 3 1011 1.65 3 102 1.69 3 1011
rs4766578 a 12 110,388,754 ATXN2 LTA SBP 0.56 0.09 2.82 3 109 V1 SBP 0.65 0.10 1.18 3 109 9.01 3 102 1.64 3 109
rs35444 a 12 114,036,820 TBX3 LTA SBP 0.55 0.09 1.47 3 108 V1 SBP 0.51 0.11 2.63 3 106 3.03 3 102 2.61 3 106
rs11072518 t 15 73,021,663 COX5A LTA SBP 0.57 0.09 6.54 3 109 V1 SBP 0.73 0.11 2.93 3 1011 1.61 3 101 6.52 3 109
rs6092743 a 20 57,133,765 C20orf174 LTA SBP 0.84 0.14 2.25 3 108 V1 SBP 1.01 0.16 2.18 3 109 1.66 3 101 2.03 3 108
rs13306561 a 1 11,788,391 MTHFR LTA DBP 0.48 0.07 2.08 3 1010 V1 DBP 0.48 0.09 1.28 3 107 2.50 3 103 1.28 3 107
rs2004776 t 1 228,915,325 AGT LTA DBP 0.35 0.06 3.20 3 108 V1 DBP 0.44 0.07 1.53 3 108 8.31 3 102 1.67 3 108
rs7599598 a 2 96,715,567 FER1L5 LTA DBP 0.31 0.05 2.91 3 108 V1 DBP 0.37 0.07 6.54 3 108 5.75 3 102 3.63 3 108
rs198823 t 6 26,230,912 HFE LTA DBP 0.33 0.06 6.57 3 109 V1 DBP 0.32 0.07 4.52 3 106 1.51 3 102 4.51 3 106
rs12258967 c 10 18,767,965 CACNB2 LTA DBP 0.35 0.06 2.48 3 109 V1 DBP 0.43 0.07 3.71 3 109 7.05 3 102 1.23 3 109
rs12244842 t 10 63,109,192 C10orf107 LTA DBP 0.38 0.06 7.05 3 109 V1 DBP 0.43 0.08 6.15 3 108 4.89 3 102 5.45 3 108
rs2681472 a 12 88,533,090 ATP2B1 LTA DBP 0.52 0.07 4.01 3 1013 V1 DBP 0.58 0.09 8.68 3 1011 5.52 3 102 8.64 3 1011
rs3184504 t 12 110,368,991 SH2B3 LTA DBP 0.39 0.05 6.08 3 1013 V1 DBP 0.39 0.07 1.26 3 108 7.50 3 103 1.26 3 108
rs1133323 t 15 72,999,278 COX5A LTA DBP 0.33 0.05 2.66 3 109 V1 DBP 0.42 0.07 4.89 3 1010 9.57 3 102 2.17 3 109
rs6092743 a 20 57,133,765 C20orf174 LTA DBP 0.50 0.08 1.11 3 108 V1 DBP 0.71 0.10 3.37 3 1011 2.04 3 101 1.11 3 108
rs880315 t 1 10,719,453 CASZ1 LTA MAP 0.46 0.07 5.49 3 1011 V1 MAP 0.43 0.08 1.47 3 107 2.86 3 102 1.47 3 107
rs13306561 a 1 11,788,391 MTHFR LTA MAP 0.61 0.08 1.83 3 1012 V1 MAP 0.57 0.10 1.48 3 108 3.94 3 102 1.48 3 108
rs2004776 t 1 228,915,325 AGT LTA MAP 0.42 0.07 1.18 3 108 V1 MAP 0.51 0.08 2.45 3 109 8.91 3 102 9.33 3 109
rs1275988 t 2 26,767,868 KCNK3 LTA MAP 0.39 0.06 1.51 3 109 V1 MAP 0.34 0.07 7.06 3 106 4.63 3 102 7.06 3 106
rs12258967 c 10 18,767,965 CACNB2 LTA MAP 0.45 0.07 4.98 3 1011 V1 MAP 0.50 0.08 5.57 3 1010 4.52 3 102 5.07 3 1010
(Continued on next page)
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Tha population predict CVD,70 LTA BP, also referred to as
‘‘usual’’ BP, has been shown to be an important predictor
of risk for future CVD events beyond single-measurement
BP levels.71 In the clinical setting, treatment for high BP
is typically recommended on the basis of repeated observa-
tions of elevated BP rather than a single elevated BP mea-
surement, given the known variability and the finding
that casual BP measurements might not reliably predict
hypertension.61,72–75 Although precision of the BP esti-
mate is improved, as we have demonstrated here, LTA
has the potential to discard information and thus diminish
signals by averaging as well. BP variability is also associated
with CVD risk, and the finding of decreased association of
signals previously linked to CVD risk (such as the 10p12
locus2) in the LTA analyses suggests that the relationship
between our findings and CVD risk might be imparted
through different mechanisms. This hypothesis would
need to be formally tested through further hypothesis-
driven laboratory experiments.
For the purposes of testing replication of our LTA find-
ings, we conducted follow-up analyses in a set of GBPG
Consortium and PUUMA cohorts not analyzed in the
LTA analyses. However, these analyses were conducted
with V1 BP results rather than LTA BP phenotypes. Also,
the GBPG Consortium included a larger number of cohorts
(17) in the replication testing than in the LTA discovery
phase, increasing the potential variation in effect size
across samples. Regardless, we confirmed association
with V1 BP traits in three of our four regions tested for
replication in samples of diverse ethnicity. The traits we
report are highly correlated, and we take the set of associa-
tions we identified as determinants of BP traits in the gen-
eral population. We compared the results of the analyses
of LTA SBP and LTA DBP to the published findings of
the International Consortium for Blood Pressure (ICBP),
which is currently the largest GWAS and meta-analysis in
individuals of European ancestry (n¼ 69,395).2 At a signif-
icance threshold of p< 53 108 in the analyses of LTA SBP
and LTA DBP, we found 19 loci uniquely identified in the
ICBP analysis (but not in our LTA analyses), ten loci iden-
tified by both the ICBP and LTA BP analyses, and six loci
uniquely identified in the LTA BP analyses. Because the
ICBP analysis also included the majority of the
cohorts in our LTA analyses, concordance of many loci
was expected.
We identified four loci in the LTA discovery analyses. We
found an intergenic variant in high LD with SNPs extend-
ing into KCNK3 (also known as TASK1), which encodes a
potassium channel, to be associated with LTA SBP and
LTA MAP. Exome sequencing studies have shown that
rare missense alleles in KCNK3 cause familial forms of pul-
monary hypertension.76 Mice null for Task1 show lower
SBP and have a defect in adrenal gland depolarization
and fail to suppress aldosterone in response to increased
dietary sodium load.77 We analyzed the data presented in
a previously published report of MAP measured invasively
in four Task1-null mice and six wild-type littermate mice78e American Journal of Human Genetics 95, 49–65, July 3, 2014 59
Figure 3. –Log p Values of Association Tests for ATP2B1 in Chromosomal Region 12q21 Demonstrate Enrichment by LTA
Plots of –log p values of association tests for LTA SBP are shown for (A) the 12q21 ATP2B1 region, known to be robustly associated with
BP, and (B) the 2p23 KCNK3 region, which was identified in this study. Both regions demonstrated enrichment of the association signal
by LTA. The results of the LTA SBP analysis are plotted in black, and the results of the corresponding V1 SBP analysis of the same indi-
viduals are plotted in blue.in an unpaired t test (unequal variance was assumed) and
found p¼ 0.0034. MAP in the Task1-null mice was approx-
imately 9 mmHg lower (SD 5 2.4 mmHg). In FER1L5,
which was associated with LTA DBP, we identified a non-
synonymous SNP (exon 21: c.2044A>G [p.Thr682Ala]) in
our GWAS analysis. FER1L5 encodes Fer-1-like 5, identified
in C. elegans, and its function has not been defined. Two60 The American Journal of Human Genetics 95, 49–65, July 3, 2014loci, near CRIP3 (chromosomal region 6p21) and IGFBP3
(chromosomal region 7p13), were associated with LTA PP.
The index SNP associated with LTA PP in the CRIP3 region
was highly correlated with a nonsynonymous SNP (exon 8:
c.563T>C [p.Ile188Thr]) in cysteine-rich protein 3 (CRIP3),
whose vascular function has not been defined. The insulin-
like growth factors (IGFs) and their binding proteins, of
which IGFBP3 is one, regulate cellular proliferation and
apoptosis, and IGF1 stimulates aortic elastin production
during development.79 The lead SNP associated with LTA
PP was in LDwith SNPs extending across the gene, suggest-
ing a possible functional variant within the gene or gene
regulatory region, although a lack of an eQTL finding
makes the latter less likely. IGFBP3 is expressed in the
endothelium, and mice null for this gene show decreased
retinal vessel growth.80 Serum levels of IGFBP3 are asso-
ciated with measures of aortic stiffness, of which PP is an
indicator,81 and a GWAS of circulating IGFBP3 amounts
in plasma showed an association with IGFBP3 SNPs we
identified.82 Circulating amounts of IGFBP3 are also
related to SBP.83 Consequently, these genes identified by
LTA analysis are highly plausible biological candidates for
BP regulation.
The limitations of this study include loss of sample size
due to the exclusion of individuals with data at only one
visit. In the longitudinal cohorts studied here, the propor-
tion lost to follow-up was low. However, bias might have
also been introduced through studying only those indi-
viduals willing or able to participate at multiple exam cy-
cles. In the discovery analyses, we used European-ancestry
samples. Ethnic differences in interindividual variability
in BP across years have not been not well defined, and
we did not have an opportunity to evaluate this in our
study. Although we gained phenotypic precision with
LTA, we might have also lost information. BP tracking
over time could be more precisely estimated with the
use of more sophisticated statistical approaches rather
than a crude average.66,67,84–90 As we demonstrated in
our LTA and V1 direct comparisons, there is overall
enrichment with LTA. However, in some specific regions,
V1 analysis yields stronger results, as assessed by lower
p values. The proportion of individuals treated with anti-
hypertensive medication increased between the first and
last visits in each cohort by varying amounts, potentially
adding to the LTA analyses variability that we did not
completely account for, although we did employ a stan-
dard correction method for antihypertensive medication
use at each visit to attempt to correct for this. Finally,
although we adjusted for age and age-squared, there
might have been other age-dependent effects, particularly
the known change in DBP that typically occurs in the
fifth decade of life91 and across which our averages were
obtained in many cases, which might explain the lower
yield with LTA for DBP than for SBP. Consequently, there
might be value in conducting parallel V1 and LTA ana-
lyses to identify BP-associated loci that are subsequently
followed up and validated by independent biological
studies.
In summary, we have evaluated the utility of averaging
repeated BP measurements for the purposes of detecting
genetic association. Alternate approaches to the study of
BP phenotypes are needed, and we have demonstrated
that LTA is useful for improving signal detection. Using
LTA of BP traits, we identified and validated commonThvariants at several known loci and at loci not previously
known to be associated with BP, and we have shown that
trait-averaging methods have important implications
for study design of genetic analyses of quantitative traits
and ultimately for improved hypothesis generation from
GWASs.Supplemental Data
Supplemental Data include 9 figures, 11 tables, cohort descrip-
tions, and Supplemental Acknowledgments and can be found
with this article online at http://dx.doi.org/10.1016/j.ajhg.2014.
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